Biologics·Aug 5, 2026
Exosome protocols are still consolidating — but a clear set of best practices has emerged around delivery, sequencing, and positioning. These are the working protocols we recommend for the most common evidence-supported uses.
Universal handling and vetting
- Verify MISEV 2023 characterization data per lot before purchase.
- Cold-chain from supplier to point of use; verify freezer temperatures and thaw protocols.
- Reconstitute per manufacturer instructions immediately before application.
- Frame the use to patients within current U.S. regulatory positioning.
Facial rejuvenation with dermal infusion
- Exosome serum reconstituted per manufacturer instructions.
- Deliver at 0.5 mm needle depth, 0.4 bar vacuum, 4–6 passes.
- Series of 3–4 sessions at 4-week intervals; quarterly maintenance.
Facial rejuvenation with microneedling
- Depth: 0.5–1.0 mm depending on region.
- Apply exosome serum during and immediately after channel creation while channels are open.
- Series of 3–4 sessions.
Post-laser and post-procedure recovery
- Topical exosome serum immediately following CO₂, fractional, or ablative resurfacing.
- Reduces re-epithelialization time and post-inflammatory hyperpigmentation risk in reported series.
- Reapply at 24 h if manufacturer permits.
Androgenic alopecia scalp protocol
- Microneedle scalp at 1.0–1.5 mm depth over affected areas.
- Apply exosome serum topically post-needling.
- Monthly ×4, then every 2–3 months for 12 months.
- Pair with topical minoxidil and, when indicated, oral 5-α reductase inhibitor.
- PRP + exosome combination protocols yield the strongest reported outcomes.
Wound care (adjunct within regulatory positioning)
- Topical exosome application to debrided wound bed as adjunct to standard care in appropriate patient selection.
- Weekly application in conjunction with amniotic membrane coverage.
- Investigational positioning; document consent and framing carefully.
Post-injection recovery (bruising, edema)
- Topical application at the injection site within 24 hours of the procedure.
- Reduces bruising duration and improves post-filler smoothness reports.
Device sequencing that improves outcome
- Dermal infusion: best combined delivery — negative pressure and continuous serum flow deposit vesicles at the DE junction.
- Microneedling: apply serum during needling while channels are open.
- Fractional laser: apply immediately post-resurfacing.
- ECSWT: shockwave preps the tissue environment; exosome delivery follows within 24–48 hours.
- HPLT / LLLT: pre-treatment with photobiomodulation supports cellular uptake and downstream response.
Head-to-head with alternatives
- vs PRP: exosome doses are consistent lot-to-lot; PRP is autologous but variable. Exosomes have not (yet) demonstrated the same MSK evidence base PRP has.
- vs amniotic: exosomes offer cell-free signaling; amniotic offers matrix + growth factors. Complementary in many aesthetic protocols.
- vs MSC-based therapies: exosomes capture most of the MSC paracrine effect without the cells; MSC-based therapy remains superior where cellular presence and integration matter.
Positioning conversations with patients
- Frame exosome use as an adjunct, delivered topically or into open channels within current regulatory positioning.
- Do not market injectable systemic exosome therapy — the evidence base and regulatory framing do not support it.
- Discuss the MISEV 2023 characterization of your product openly.
- Track outcomes with photographs, patient-reported measures, and durability at 3 and 6 months.
Common failure modes
- Using non-characterized supplier product — outcome variability and safety unknown.
- Interrupting the cold chain — vesicle integrity is temperature sensitive.
- Injecting for systemic effect outside the evidence base and regulatory framing.
- Overpromising results and undermining the practice's credibility.